1. Kalypsys, Inc. (14 from 17 patents)

2. Synaptic Pharmaceutical Corporation (8 from 126 patents)

3. Other (1 from 832,912 patents)

4. Novartis Ag (1 from 3,923 patents)

5. H. Lundbeck A/s (1 from 507 patents)

6. Alcon Laboratories, Inc. (1 from 449 patents)

7. H. Lunbeck A/s (1 from 4 patents)

8. H. Lundbick A/s (1 from 1 patent)

9. Civi Biopharma, Inc. (1 from 1 patent)

10. Bharat Lagu (0 patent)

11. Hermo Jimenez (0 patent)

12. Kitae Lim (0 patent)

13. John M. Wetzel (0 patent)

14. Stewart Noble (0 patent)

15. Michael Konkel (0 patent)

1. 12291708 - Oral delivery of antisense conjugates targeting PCSK9

2. 9078887 - Bicyclic heteroaryl inhibitors of PDE4

3. 8569300 - Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease

4. 8258154 - Bicyclic heteroaryl inhibitors of PDE4

5. 8138205 - Heteroarylalkoxy-substituted quinolone inhibitors of PDE4

6. 8080563 - Bicyclic heteroaryl inhibitors of PDE4

7. 8080566 - Carbazole inhibitors of histamine receptors for the treatment of disease

8. 7915253 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR

9. 7834004 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR

10. 7825256 - Inducible nitric oxide synthase dimerization inhibitors

11. 7745646 - Bicyclic heteroaryl inhibitors of PDE4

12. 7494999 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR

13. 7470722 - Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease

14. 7381749 - Sulfonamides as inhibitors of histone deacetylase for the treatment of disease

15. 7273880 - Selective NPY (Y5) antagonists